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ABSTRACT
Objective: To evaluate the performance and cost of
an HIV reverse transcriptase-enzyme activity (HIV-RT)
assay in comparison to an HIV-1 RNA assay for
routine viral load monitoring in resource limited
settings.
Design: A cohort-based longitudinal study.
Setting: Two antiretroviral therapy (ART) centres in
Karnataka state, South India, providing treatment under
the Indian AIDS control programme.
Participants: A cohort of 327 HIV-1-infected Indian
adult patients initiating first-line ART.
Outcome measures: Performance and cost of an
HIV-RT assay (ExaVir Load V3) in comparison to a
gold standard HIV-1 RNA assay (Abbott m2000rt) in a
cohort of 327 Indian patients before (WK00) and
4 weeks (WK04) after initiation of first-line therapy.
Results: Plasma viral load was determined by an HIV-
1 RNA assay and an HIV-RT assay in 629 samples
(302 paired samples and 25 single time point samples
at WK00) obtained from 327 patients. Overall, a strong
correlation of r=0.96 was observed, with good
correlation at WK00 (r=0.84) and at WK04 (r=0.77).
Bland-Altman analysis of all samples showed a good
level of agreement with a mean difference (bias) of
0.22 log10copies/mL. The performance of ExaVir Load
V3 was not negatively affected by a nevirapine/efavirenz
based antiretroviral regimen. The per test cost of
measuring plasma viral load by the Abbott m2000rt
and ExaVir Load V3 assays in a basic lab setting was
$36.4 and $16.8, respectively.
Conclusions: The strong correlation between the HIV-
RT and HIV-1 RNA assays suggests that the HIV-RT
assay can be an affordable alternative option for
monitoring patients on antiretroviral therapy in
resource-limited settings.
Trial registration number: ISRCTN79261738.
INTRODUCTION
The principal aim of antiretroviral therapy
(ART) is durable suppression of replicating
plasma virus to undetectable levels, thereby
delaying disease progression and prolonging
survival.1 2 Expanding access to ART in
resource-limited settings along with close
monitoring is needed for successful treat-
ment outcomes. In high income settings, this
is achieved by performing quantitative viral
load monitoring every 3–6 months,3 as viral
load monitoring detects early treatment
failure. However, in resource-limited settings,
therapeutic outcome is evaluated either on
the basis of a CD4 T cell count or clinical
ﬁndings,4 neither of which accurately pre-
dicts viral suppression.5 Early detection of
viral failure by monitoring the viral load also
provides the opportunity to intensify adher-
ence counselling to improve adherence to
ART, potentially leading to resuppression of
viral load before the evolution of
drug-resistant virus can take place.6
The currently used viral load assays are
based on the ampliﬁcation of HIV-1 virion
Strengths and limitations of this study
▪ To the best of our knowledge, the current study
is the most thoroughly evaluated study of ExaVir
Load V3 HIV reverse transcriptase-enzyme activ-
ity (HIV-RT assay) from India to date.
▪ This study was performed in a large number of
patients in a longitudinal manner looking into
the effects of the non-nucleoside reverse tran-
scriptase inhibitors-based therapy and drug
resistance mutations on the performance of the
HIV RT-enzyme activity assay.
▪ Though the assay has been validated before in
other non-C subtype settings, in this study the
HIV-RT assay was validated on a larger scale in
a subtype C predominant setting and subtype C
is the most predominant subtype globally, more
so affecting the resource-limited settings.
▪ This study was limited to patients hailing from
Southern India and a performance evaluation
and cost-effectiveness of the HIV-RT assay
needs to be accessed on a national level.
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RNA, which is considered impractical for wide-scale use
in resource-limited settings, as it requires infrastructure,
facilities for molecular diagnostics, expensive equipment
and skilled technicians, which are often unavailable.7
Simpler, less expensive viral load assays would be very
useful in the resource-limited environments that are
most impacted by this epidemic.
An alternative to measure the HIV-1 RNA is to
measure the activity of the viral reverse transcriptase
(RT) enzyme. The ExaVir Load assay (Cavidi, AB,
Sweden), a low-cost and technically less demanding
assay using an ELISA-based method to measure RT
enzyme activity, has shown promising results.8–19
Although previous versions of the test have been evalu-
ated against several PCR-based HIV tests that measure
viral RNA, there are few comparative studies between
ExaVir Load V3 and such molecular real-time
assays.14 16 18 The most recent V3 of the ExaVir Load
assay has an enhanced sensitivity (lower detection limit
200 copies/mL) and reduced turnaround time com-
pared to V2.14 18
HIV-1 subtype C (HIV-1C) is the dominant strain in
most low and middle income countries like India, South
Africa and Ethiopia,20 and the need for a simple low
cost viral load monitoring tool is a priority in these set-
tings. Data available from countries dominated by the
HIV-1C epidemic are limited. Where available, evalua-
tions have been mainly performed with earlier version
assays (ExaVir Load V1 and V2), which had lower detec-
tion limits of 400 copies/mL.7 11 21 22 Studies evaluating
Exavir Load V3 have been mainly performed in non-C
dominated countries.14 16 18 19
Thus, we aimed to evaluate the performance of the
HIV RT-enzyme activity (HIV RT) assay (ExaVir Load
V3) in comparison to a ‘gold standard’ HIV RNA load
(Abbott m2000rt real-time PCR) assay in a cohort of
patients before and after initiation of ﬁrst-line ART in
Indian settings. We also compared viral load measure-
ments from both assays in a subset of patients with
drug-resistant mutations at baseline. Further, we studied
the difference in costs of the two viral load assays in the
context of our laboratory setting from a provider
perspective.
MATERIALS AND METHODS
Study participants and samples
Between April 2010 and September 2011, EDTA plasma
samples were collected from HIV-1-infected adult
patients attending the Infectious Disease Clinic,
St. John’s Medical College and Hospital, Bangalore
(main site) and ART centre, Krishna Rajendra Hospital,
Mysore (peripheral site) enrolled in the HIVIND rando-
mised controlled trial (Trial registration:
ISRCTN79261738).23 All the patients included in the
study initiated ART with reverse transcriptase inhibitor
(RTI) drugs, that is, two nucleoside reverse transcriptase
inhibitors (NRTI), zidovudine (AZT) or stavudine (d4T)
with lamivudine (3TC) + one non-nucleoside reverse
transcriptase inhibitor (NNRTI), either nevirapine
(NVP) or efavirenz (EFV) as per the standard national
AIDS programme guidelines.24
Plasma samples were collected at two time points; (1)
prior to ART initiation (not longer than 3 months prior)
and (2) 4 weeks after ART initiation. The plasma
samples were separated within 6 h of EDTA whole blood
collection, aliquoted and stored at −80°C in the main
site. Plasma samples aliquoted in the peripheral site
were stored at −20°C and transported to the main site
on dry ice (every 2 weeks) and then stored at −80°C
prior to testing.
Ethical statement
Ethical approvals for the conduct of the trial were
obtained from the Institutional Ethical Review Board of
St John’s Medical College Hospital, Bangalore (IERB 1/
369/08-92/2008) and Krishna Rajendra Hospital,
Mysore (NO/PS/173/2010). All patients participating in
the HIVIND study have given their written consent.
Plasma HIV-1 RNA assay
Plasma HIV-1 RNA load was measured in the patient
cohort using the Abbott Real-Time PCR, m2000rt system
with a manual RNA extraction procedure on an
m2000sp sample preparation system as per the manufac-
turer’s instructions. The assay was performed using an
initial volume of 0.2 mL plasma, which provides limits
of quantiﬁcation between 150 copies/mL (lower limit of
detection) and 10 000 000 copies/mL (upper limit of
detection). In every run, a negative control, a low posi-
tive control and a high positive control supplied in the
Abbott Realtime HIV-1 control kit were included. This
measure using Real-Time PCR was considered as the
gold standard. This protocol was validated by an external
quality control programme by the Quality Control for
Molecular Diagnostics, Glasgow, Scotland (QCMD,
http://www.qcmd.gov) on a 2010 panel (Consisting of
four HIV-1B samples, two HIV-1C samples, one HIV-1A/
G sample and one HIV-1 negative sample) and obtained
a highly satisfactory score.
Plasma HIV RT enzyme activity assay
The viral RT enzyme activity was quantiﬁed using Cavidi
ExaVir Load V3 as per the instructions of the manufac-
turer.14 In an ELISA-based format, the RT activity of the
RT enzyme recovered from 1 mL of patient plasma was
determined and compared to a standard curve based on
known amounts of an HIV 1 recombinant RT
constructed from the BH10 isolate. The RT activity in
the sample was expressed as femtogram HIV-1 RT
activity/mL (fg/mL) plasma that was translated into
RNA copies/mL equivalent by the ExaVir Load analyser
software. The lower detection limit of the assay was
≥1fg/mL that is, ≥200 copies/mL. In every run, a single
positive control and a negative control were used to
monitor the performance of the RT extraction process
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and to access between run variations. The positive
control was prepared by pooling the EDTA plasma from
a high HIV-1 viral load sample and HIV-1 negative
plasma; 1.2 mL was aliquoted and stored in a −80°C
freezer. The laboratory personnel running the ExaVir
Load V3 assay were blind to the plasma HIV-1 RNA
values.
HIV-1 subtyping and baseline drug resistance
Genotypic resistance testing (GRT) was performed on
the baseline plasma samples. Brieﬂy, the reverse tran-
scriptase (RT) region of the HIV-1 pol gene was ampli-
ﬁed and sequenced using the primers described by us
previously.25 HIV-1 subtyping was determined on the
basis of the pol gene as well as the env gene (wherever
sequence data were available).26–28 using the maximum
likelihood (ML) phylogenetic tree based on reference
sequences downloaded from the Los Alamos Database
(http://www.hiv.lanl.gov). Primary drug resistance ana-
lysis was evaluated using the WHO list of mutations from
2009 (WHO_SDRM 2009).29
Comparative cost analysis
We did an analysis comparing the costs between Abbott
m2000rt and ExaVir Load V3 from a provider (labora-
tory service provider) perspective. We used costs from
our lab for this purpose. Costs considered included
annuitised capital costs for the two different instruments
including operator-supplied instruments. These are
instruments which are necessary in case of a new labora-
tory. In case of Abbott, the operator-supplied instru-
ments included single-channel micropipettes, two dry
baths and a vortex. For ExaVir Load V3, they included
micropipettes (both single-channel and multichannel),
an ELISA plate reader, an incubator, a rocker and a
vortex.
Costs for start-up kits, human resource costs (includ-
ing time for training), annual maintenance, reagents
and other consumables were also considered. We
assumed the working life for Abbott m2000rt and
ExaVir Load V3 to be 5 years, and a discount rate of 5%
was applied.
Assumptions
Number of patients: There are at present 1500
ART-experienced patients in our ART centre. Assuming
that viral load monitoring of these patients will require
to be performed every 6 months, there will be 3000
samples a year.
Maintenance costs: In the case of Abbott m2000rt the
costs for servicing, maintenance of instrument and cali-
bration of laser head. In the case of Abbott m2000rt the
annual maintenance cost included the costs for ser-
vicing, maintenance of instrument and callibration of
laser heads.
Human resource skills and training requirements:
From our experience, 1 month was required to train a
technician on Abbott m2000rt. One week was required
for training on ExaVir load V3. We also considered that
the technician handling Abbott m2000rt would require
to be more senior and experienced (salary $300 per
month) compared to the technician working with
ExaVir Load V3 (salary $200 per month).
Time for each method of testing: For Abbott m2000rt,
a batch of 24 reactions which comprise 21 samples and
3 controls will involve a total time of 8 h (from the
beginning of RNA extraction up until obtaining results),
of which 5 h involve the technician’s time. For Exavir
Load V3, the assay is performed in batches of 30
samples. Though the turnaround time is 48 h, it involves
5 h of actual hands-on time per batch. Costs for time of
the technicians were calculated against the salaries men-
tioned above.
In the cost comparison analysis, we did not consider
costs associated with the sample collection, storage and
transportation as these are common to both tests.
Statistical analysis
All statistical analyses were performed after the HIV RT
and HIV-1 RNA level values were log10 transformed. For
analysis, the lower limit of detection of the HIV RT assay
(≤200 copies/mL) was considered; samples showing
<200 copies/mL by any of the assays were assigned a
value of 199 copies/mL. With Exavir Load V3, we
achieved a varying upper detection limit ranging from
>360 000 to >770 000 in different runs. Thus, samples
with a viral load of >360 000 (the lowest range of the
upper detection limit obtained for ExaVir Load V3) by
any of the assays were assigned a viral load of 360 000
copies/mL. The diagnostic agreement between the HIV
RT assay and the HIV-1 RNA assay at different viral load
cut-offs was determined from the κ statistic. Pearson’s
correlation coefﬁcient (r) was calculated to study the
correlation between log10 HIV RT activity (copies/mL
equivalents) and log10 HIV RNA (copies/mL). However,
since this coefﬁcient does not take into account the pos-
sibility that one measure may differ consistently from the
other, we further assessed the level of agreement using
pairwise Bland-Altman plots. This plot compares the
measures between the two tests by plotting the differ-
ence in the two VL measures against the average of the
two measures.
RESULTS
Sample characteristics
Plasma viral load was obtained from 629 samples col-
lected from 327 HIV-1-infected adult patients, of which
302 were paired (before ART and 4 weeks after ART ini-
tiation). HIV-1C was the predominant subtype observed
in 98.1% (313/319) of the patients. Six out of 319 geno-
typed patients (1.9%) showed the presence of non-C
subtype strains, namely BC recombinant (1), BD recom-
binant (1), A1C recombinant (2) and HIV-1A1 (2).
Eleven patients (3.4%) showed the presence of single
primary drug-resistant mutations, with six samples
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harbouring NRTI-associated drug-resistant mutations
(DRMs) and ﬁve samples with NNRTI-associated muta-
tions (table 1).
Comparison between HIV RT activity and HIV-1 RNA load
assay
There were 54 samples (8.5%) that were quantiﬁable by
the HIV-1 RNA assay but were below the detection limit
of the HIV RT assay (table 2). At a lower limit of quanti-
ﬁcation of 200 copies/mL, 90.7% of the samples showed
a quantiﬁable virus by the HIV RT assay. The percentage
of the samples with a quantiﬁable viral load by the HIV
RT assay increased with higher viral load cut-offs by the
HIV-1 RNA assay as shown in table 2. Overall, there was
acceptable agreement observed between the HIV RT
and HIV-1 RNA assays, with excellent agreement
observed at higher values of plasma viral load ≥3.0 log10-
copies/mL (κ=0.76). Of all the samples, 81.7% (514/
629) had viral load values by the HIV RT assay, which dif-
fered by<0.5 log10 units from the HIV-1 RNA values,
while 99.2% (624/629) of the samples differed by <1.0
log10 units.
A strong positive correlation was observed between the
plasma viral load values by the HIV RT and HIV-1 RNA
assays (r=0.96) in all the samples. A good correlation was
noted in ART-naïve samples (r=0.84) as well as in
samples at week 04 of ART (r=0.77; ﬁgure 1).
Bland-Altman plots for all the samples showed good
levels of agreement with a mean difference (bias) of
0.22 log10copies/mL, with acceptable limits of agree-
ment (−0.45 and +0.89 log10copies/mL). A good level
of agreement was also observed separately at baseline
(mean difference bias of 0.25; range of acceptable limit
of agreement: −0.39 and +0.89 log10copies/mL) and at
WK04 (mean difference bias of 0.19; range of acceptable
limit of agreement: −0.52 and +0.89 log10copies/mL;
ﬁgure 2).
Influence of current ART and drug-resistant mutations on
RT-enzyme activity
Table 1 shows that the mean log10 difference between
the HIV RT and HIV-1 RNA assays both before and after
initiation of ART was not signiﬁcantly different (<0.25
log10 copies/mL) but was well within the clinically
accepted limit of 0.5 log10copies/mL. Thus, the per-
formance of the HIV RT assay is not affected by the pres-
ence of the NNRTI (nevirapine/efavirenz)-based ART
regimen. Also, the presence of either NRTI-associated
DRMs (n=6; M41L: 1, D67N: 1, T69D: 1, M184I: 1 and
T215S: 2) and NNRTI-associated DRMs (n=5; Y181C: 1,
K101E: 1 and K103N: 2) showed an acceptable change
Table 1 Comparison of HIV-1 plasma VL levels measured by the HIV RT and HIV-1 RNA assays by ART status, HIV-1
subtypes and RT-drug resistant mutations
Sample type Number of samples
Mean viral load±SD in
log10copies/mL
Mean log10 viral load
difference±SD in
log10copies/mLExaVir Load V3 Abbott m2000rt
All samples 629 3.98±1.3 4.19±1.3 0.22±0.3
ART Status
Naïve (baseline at WK00) 327 5.07±0.6 5.33±0.5 0.25±0.3
Experienced (WK04) 302 2.79±0.5 2.97±0.6 0.19±0.4
Subtype at WK00 (n=319)*
C 313 5.08±0.6 5.33±0.4 0.25±0.3
Non-C 6 5.05±0.5 5.3±0.4 0.25±0.3
DRMs at WK00 (n=319)*
Wild type (no DRM) 308 5.07±0.6 5.32±0.5 0.25±0.3
NRTI mutations 6 5.41±0.3 5.55±0.01 0.15±0.3
NNRTI mutations 5 5.26±0.2 5.62±0.2 0.36+0.2
*Genotyping performed only in baseline samples.
ART, antiretroviral therapy; DRM, drug-resistant mutations, NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse
transcriptase inhibitors; RT, reverse transcriptase; VL, viral load.
Table 2 Agreement between the HIV RT assay and HIV-1 RNA assay at different PVL levels
PVL by HIV-1 RNA
In copies/mL (log10 copies/mL) Agreement κ Value
Number of samples
detected by Abbott m2000rt
Percentage of Samples
detected by ExaVir Load V3
≥200 (2.3) 89.1 0.46 580 90.7
≥400 (2.6) 88.1 0.57 550 93.5
≥1000 (3.0) 89.7 0.76 458 97.6
≥5000 (3.7) 94.4 0.89 344 99.7
≥10 000 (4.0) 96.8 0.94 324 100
PVL, plasma viral load; RT, reverse transcriptase.
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(<0.4 log10 copies/mL) in mean log10 difference
from the corresponding value among wild types.
Although the samples with mutations are small, it indi-
cates that the presence of NRTI and NNRTI DRMs did
not negatively impact the test performance.
Cost comparison of the assays
The laboratory cost of viral load monitoring of
HIV-infected patients analysed in our cohort by both
Abbott m2000rt (HIV-1 RNA) and ExaVir Load V3
(HIV RT) is shown in table 3. The per test cost of the
plasma viral load measured by Abbott m2000rt and
ExaVir Load V3 was $36.4 and $16.8, respectively. Thus,
by using ExaVir Load V3, $19.6 per test can be saved. In
a laboratory with a pre-existing basic set-up for
ELISA-based assays, ExaVir Load V3 can be performed
at $16.1, saving $20.2 per test. Most of the expense saved
by using ExaVir Load V3 was due to (1) lower capital
costs (instruments $37 750 against $2000) (2) the lower
cost of the assay reagents ($15/test against $31/test;
table 3).
Figure 1 Correlation between the Abbott m2000rt and
ExaVir Load V3 assays for (A) all 629 samples showing
r=0.96 (B) 327 baseline (WK00) samples showing r=0.84 and
(C) 302 4-weeks post-ART (WK04) samples showing r=0.77.
ART, antiretroviral therapy.
Figure 2 Bland-Altman plot with 95% CI of limits of
agreement between HIV-1 viral loads measured with the
Abbott Real-Time m2000rt assay and the ExaVir Load V3
assay for (A) all 629 samples showing a mean bias of 0.22
with 95% limits of agreement ranging from −0.45 to 0.89 (B)
327 baseline (WK00) samples showing a mean bias of 0.25
with 95% limits of agreement ranging from −0.39 to 0.89 (C)
302 4 weeks post-ART (WK04) samples showing a mean bias
of 0.19 with 95% limits of agreement ranging from −0.52 to
0.89. ART, antiretroviral therapy.
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DISCUSSION
A good correlation between the HIV RT and HIV-1 RNA
assays was observed in the current HIV-1C predominant
setting in India. The agreement between the tests was
not signiﬁcantly affected by the NRTI/NNRTI-based
antiretroviral regimen used. Earlier studies performed
on panels of different subtypes and recombinants have
suggested that the HIV RT assay detects all HIV-1 and
HIV-2 subtypes with similar efﬁciency.14 15 30 This assay,
ExaVir Load V3, can therefore be an attractive option
for viral load monitoring in Indian settings.
This study compared the ExaVir Load V3 assay with the
Abbott m2000rt HIV-1 RNA assay and observed an excel-
lent correlation (r=0.96). An earlier study from London
comparing the same tests observed a similar correlation
(r=0.94).14 Strong correlations between the ExaVir Load
V3 and Roche HIV-1 RNA-based assays have also been
observed by two other studies, by Greengrass et al18 from
Australia (Roche Cobas Amplicor; r=0.85) and Huang
et al16 from China (Roche Cobas TaqMan 48; r=0.95).
Neither of these studies was performed in HIV-1C domi-
nated settings. The HIV RT assay showed a good agree-
ment with the HIV-1 RNA assay at the clinically important
viral load threshold of 1000 copies/mL, which is used by
the WHO to deﬁne viral failure to ﬁrst-line therapy and is
also most often used as the cut-off for drug resistance
genotyping.31 The performance of the Exavir Load
below 1000 copies/mL is moderate.
In general, we observed an underestimation of viral
load of 0.22 log10 RNA copies by the HIV RT assay,
which is similar to what has been observed in other
studies.14 16 32 These two surrogate assays use very differ-
ent methods for quantifying the plasma viral load. The
HIV-1 RNA assays quantify the amount of viral RNA irre-
spective of RNA functionality, while the HIV RT assay
quantiﬁes the amount of active RT enzyme. The
calibration constant used to translate RT activity into
RNA copies was estimated from a study of an Australian
cohort18 and is not completely accurate for all combina-
tions of HIV RNA assays and cohorts with varying
subtype compositions. The variation observed is,
however, well within the acceptable limit of <0.5 log10
copies.
NNRTI drugs bind to the RT enzyme, inhibit its activ-
ity and prevent viral replication. Several articles have dis-
cussed the possibility that enzymatically inactive RT drug
complexes could result in under quantiﬁcation of RT in
relation to RNA.29 30 33 These studies were, however,
cross-sectional and never found any evidence for
reduced RT activity during NNRTI therapy. In contrast
to previous cohorts, the longitudinal sampling in our
study provides optimal material for evaluation of the
effects of NNRTI-based drug regimens. When compar-
ing HIV viral load data from the same patient cohort
before and after onset of ART, we found a mean log10
difference between ExaVir Load V3 and Abbott m2000rt
of 0.25 for naïve patients and 0.19 for experienced
patients (table 1). Thus, the difference between the tests
did not increase after onset of therapy. This supports evi-
dence that the current NNRTI containing therapy does
not adversely inﬂuence the recovery of RT enzyme
activity.
On a small number of samples, we assessed if the pres-
ence of drug-resistant mutations decreased the RT
ﬁtness so as to inﬂuence the performance of the HIV
RT assay. We had six samples with single NRTI mutations
and ﬁve samples with single NNRTI mutations and
observed no evidence that their presence caused any sig-
niﬁcant difference in the association between RT
enzyme activity and HIV-1 RNA load. These results were
not unexpected and support evidence from previous
studies by Napravnik et al and Rooijen et al indicating
that the presence of NRTI or NNRTI mutations do not
affect the relationship between RT enzyme activity and
HIV-1 RNA load.34 35 Resistance to NRTIs is mediated by
a primitive DNA editing function that is introduced into
the HIV RT by certain mutations. An energy dependent
base excision reaction removes the last base in the
growing DNA chain. This requires an energy donator,
usually ATP or GTP, and might decrease RT reaction vel-
ocity. This happens readily in vivo, but the reaction con-
ditions in the current RT assay do not support this
reaction.36
To the best of our knowledge, this is the most thor-
oughly evaluated study of ExaVir Load V3 from India to
date. Thus far, there have been three comparative
studies from India that have been reported from the
states of Andhra Pradesh (Anantpur),37 Tamil Nadu
(Chennai)7 and New Delhi.32 Iqbal et al7 from Chennai
cross-sectionally evaluated the ExaVir Load assay V1 and
Roche Amplicor Monitor assay. They found a good
agreement between the two tests and a signiﬁcant
inverse correlation between ExaVir Load and CD4+
T-cell count. Alvarez-Uria et al37 from Anantpur
Table 3 Cost comparison between the HIV RT assay and
HIV-1 RNA assay for a laboratory doing 3000 tests/year
Cost items ($)
Abbott
m2000rt Cost
($)
ExaVir Load
V3 Cost ($)
Annuitised costs of
capital instruments
8719 462
Annuitised cost of
operator supplied
instruments
293 1540
Annual maintenance cost 1126 666
Costs of kits per year 93 000 45 000
Consumables per year 4616 1846
Training time for lab staff
to run the test
300 50
Salary costs (3000 tests
per year)
1200 1000
Total ($) 109 634 50 534
Cost/test ($) 36.4 16.8
US$1=60 INR.
RT, reverse transcriptase.
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compared the accuracy of ExaVir V3 with Roche Cobas
TaqMan HIV-1 test and Roche Amplicor HIV-1 DNA
assay for early infant diagnosis. ExaVir performed well
showing 100% sensitivity and 99% speciﬁcity, but no
quantitative correlations were evaluated. A more recent
study by Kokkayil et al32 compared ExaVir Load V3 with
Roche Cobas TaqMan among 75 ART naïve patients and
reported no statistically signiﬁcant difference between
the two assays.
There are a few drawbacks of the HIV RT assay. The
long turnaround time of 48 h makes it appear labour
intensive, though the actual hands-on time is approxi-
mately 5 h. The prolonged incubation time is critical to
achieve assay sensitivity. For standard performance, the
assay requires 1 mL of plasma, which is high in compari-
son to the requirement for HIV-1 RNA assays, thus limit-
ing its possible usefulness in paediatric populations.
However, a recent study by Greengrass et al19 observed
that sample volumes down to 0.25 mL with VL >800
copies/mL can be utilised for paediatric monitoring.
The ExaVir Load assay does not provide a standard posi-
tive and negative control, thus requiring the lab to
prepare its own controls, which may compromise the
quality assurance of the assay. Additionally, we noted that
the quality of the water used for washing is important as
impurities and bacterial contaminants present in water
may contain polymerases which can create background
noise and increase the level of the lower detection limit.
In spite of these caveats, the HIV RT assay has advan-
tages over the HIV-1 RNA assays in resource-limited set-
tings because it is an ELISA-based assay and can be
performed in any routine lab at a lower cost. The ExaVir
Load assay requires a cheaper and maintenance free
start-up kit as compared to real-time assays. We observed
that performing the HIV RT assay routinely in our
centre would save us $20.2 per sample as compared to
an HIV-1 RNA assay. A more basic laboratory, which
requires installing basic ELISA equipment, would save
$19.6 per sample (table 3).
The use of CD4 cell count as a prognostic marker has
been debated; it is argued that this count may not reﬂect
the actual viral load status of the patient.38 The cost asso-
ciated with viral load monitoring using HIV-1 RNA assays,
despite being lower than PCR assays, is a major limiting
factor for its implementation. Currently, in India, viral load
testing has been phased in to support patients failing ﬁrst-
line ART. In the year 2012, about 4157 viral load tests were
performed under the National AIDS Control Organisation
(NACO).39 Considering that $19.6 could have been saved
per sample by performing an HIV RT assay, the cost saving
for these 4157 viral load tests could have amounted to $
81 477 if an HIV RTassay had been used.
In our cost-comparison analysis, we have used a pro-
vider perspective (lab service). We acknowledge that this
is a narrower perspective than a societal one, which
would include patient costs, opportunity costs among
other costs. However, the purpose of our analysis was to
provide information to laboratories in resource
constrained settings, often faced with decisions in the
face of tight budgets, and thus a societal perspective was
not considered necessary. A laboratory manager faced
with a limited budget would concentrate entirely on
costs that have an immediate impact on her/his own
budget; this is the perspective adopted in this study.
NACO is now considering taking up the monitoring
approach recommended by the WHO to diagnose and
conﬁrm ART failure. Considering that there are cur-
rently 604 987 HIV-1-infected individuals receiving ﬁrst-
line ART at 380 centres spread across the country, the
cost reduction of utilising HIV RT compared to HIV
RNA plasma load can be substantial.40
Scaling up ART requires the critical support of HIV-1
viral load monitoring. Evidence from the comparative
performance of the HIV RT assay with HIV-1 RNA assays
from ours and other studies from India indicates that
the ExaVir Load assay could serve as an affordable alter-
native to monitor patients on ART.
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